USPSTF Recommendations for Aspirin Use Vary by Age

Share this content:
USPSTF Recommendations for Aspirin Use Vary by Age
USPSTF Recommendations for Aspirin Use Vary by Age

TUESDAY, Sept. 15, 2015 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) has concluded that the benefits and harms of low-dose aspirin for prevention of cardiovascular disease (CVD) and cancer vary by patient age. These findings form the basis of a draft recommendation statement published online Sept. 14 by the USPSTF.

Researchers from the USPSTF reviewed the evidence relating to use of low-dose aspirin to prevent CVD and cancer. They then prepared recommendations that address different age groups.

The researchers found that for adults aged 50 to 59 years who have a 10 percent or greater 10-year CVD risk and are not at increased risk for bleeding, low-dose aspirin should be taken to prevent CVD and colorectal cancer (Grade B recommendation). For individuals aged 60 to 69 years with a greater than 10 percent 10-year CVD risk, the decision to use low-dose aspirin should be an individual one (Grade C recommendation). For adults younger than 50 years and for those age 70 years and older, the current evidence was insufficient to weigh the balance of benefits and harms of aspirin use (Grade I statements). These findings form the basis of the draft recommendation statement, which will be available for comment until Oct. 12.

"Taking aspirin is easy, but deciding whether or not to take aspirin for prevention is complex," task force vice chair Kirsten Bibbins-Domingo, Ph.D., M.D., said in a statement.

Draft Recommendation Statement
Draft Evidence Review 1
Draft Evidence Review 2
Draft Evidence Review 3

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »